Survival and glycemic control in patients with coexisting melanoma and diabetes mellitus

Nina J. Karlin, Aaron R. Mangold, Shailja B. Amin, Heidi E. Kosiorek, Matthew R. Buras, Patricia M. Verona, Curtiss B. Cook

Research output: Contribution to journalArticlepeer-review

4 Scopus citations

Abstract

Aim: Given the lack of data in the literature, we examined the impact of diabetes mellitus (DM) on melanoma survival and the impact of melanoma on glycemic control. Materials & methods: Patients with melanoma with and without DM were matched 1:1 (2005-2016). Kaplan-Meier analysis was used to estimate overall survival and progression-free survival (PFS). Mixed models compared hemoglobin A1c (HbA1c) and glucose measures over time. Results: Mean HbA1c during the year after cancer diagnosis was 6.7%. The 5-year PFS rate was 89% (95% CI: 81-99%) for patients with DM and 63% (95% CI: 51-79%) for patients without DM (p = 0.02). Conclusion: Melanoma did not adversely impact glycemic control. The DM did not adversely impact survival of patients with melanoma, although increased PFS for melanoma was seen in individuals with DM. The objective of this study was to identify the effect of diabetes mellitus (DM) on survival of patients with melanoma and to determine whether melanoma and its treatment affected glycemic control. We used an institutional cancer registry to identify 112 patients with melanoma and grouped them by the presence (n = 56) or absence (n = 56) of DM. Patients were matched by age and year of melanoma diagnosis. For individuals with melanoma, DM did not decrease survival rates, and the diagnosis of melanoma did not affect glycemic control.

Original languageEnglish (US)
Article numberFSO368
JournalFuture Science OA
Volume5
Issue number3
DOIs
StatePublished - 2019

Keywords

  • cancer
  • diabetes mellitus
  • endocrinology
  • glucose
  • malignancy
  • mortality
  • outcomes research

ASJC Scopus subject areas

  • Biotechnology

Fingerprint

Dive into the research topics of 'Survival and glycemic control in patients with coexisting melanoma and diabetes mellitus'. Together they form a unique fingerprint.

Cite this